GALECTIN THERAPEUTICS INC (GALT): Results of Operations and Financial Condition
GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20080011_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics
How this was made
The 30-second read
Why it matters
The 8-K highlights FDA alignment on Phase 3 trial design elements (primary endpoint, blinded central endoscopy review for varices, and a 2 mg/kg LBM dose) and sets an expected 3Q 2026 protocol submission timeline, which can materially change perceived regulatory and execution risk.
Market read
Traders can update models for belapectin’s regulatory path and near-term execution milestones, while also factoring dilution from the debt conversion and the company’s cash runway through June 2027.
What to watch
The debt-to-equity conversion strengthens the balance sheet but increases share count, which can cap upside even if regulatory risk declines.
Background
Galectin Therapeutics is developing belapectin, a galectin-3 inhibitor, for MASH cirrhosis with portal hypertension; the company is moving from NAVIGATE Phase 2b/3 into a registrational Phase 3.
Ticker impact
Galectin Therapeutics says it reached agreement with the FDA on Phase 3 belapectin trial design for MASH cirrhosis and portal hypertension.
Bias to positive near-term repricing as traders price in reduced regulatory risk and the upcoming protocol submission timeline.
The filing is a fresh 8-K with specific FDA-agreed Phase 3 endpoint and central endoscopy review details, plus an explicit expected submission window in 3Q 2026.
Market effects
Reinforces regulatory-path clarity for galectin-3 targeted liver disease programs, potentially improving sentiment for small-cap hepatology biotechs.
Limited, primarily US small-cap biotech sentiment.
Moderate, as EASL presentations and journal publications support broader scientific validation but the regulatory decision is US-focused.
Counterpoint
FDA agreement on trial design does not guarantee Phase 3 success, and the company still reports a sizable net loss and relies on limited cash runway.
Key entities
- companyGalectin Therapeutics, Inc.
NASDAQ-listed developer of belapectin for MASH cirrhosis and portal hypertension.
- drug_programBelapectin
Galectin-3 targeted complex carbohydrate drug in Phase 3 planning for MASH cirrhosis with portal hypertension.
- regulatorU.S. Food and Drug Administration (FDA)
Agreed on key elements of the planned Phase 3 trial design for belapectin.
- insiderRichard E. Uihlein
Chairman and largest stockholder who converted about $105.8 million of debt and accrued interest into common stock effective July 31, 2026.
